# **PRODUCT** INFORMATION



Nedocromil (sodium salt)

Item No. 24005

CAS Registry No.:	69049-74-7	
Formal Name:	9-ethyl-6,9-dihydro-4,6-dioxo-10- propyl-4H-pyrano[3,2-g]quinoline-2,8- dicarboxylic acid, disodium salt	
MF:	C <sub>19</sub> H <sub>15</sub> NO <sub>7</sub> ● 2Na	
FW:	415.3	
Purity:	≥98%	
UV/Vis.:	λ <sub>max</sub> : 251, 286, 339, 372 nm	
Supplied as:	A crystalline solid	$\Pi \sim \Pi$
Storage:	-20°C	0 <sub>• 2Na</sub> + 0
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

# Laboratory Procedures

Nedocromil (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the nedocromil (sodium salt) in the solvent of choice, which should be purged with an inert gas. Nedocromil (sodium salt) is soluble in organic solvents such as ethanol and DMSO. The solubility of nedocromil (sodium salt) in these solvents is approximately 30 and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of nedocromil (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of nedocromil (sodium salt) in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

# Description

Nedocromil is a mast cell stabilizer.<sup>1</sup> It inhibits IgE-induced histamine release from rat peritoneal mast cells cocultured with 3T3 cells (MC/3T3) and preincubated with IL-2 when used at a concentration of 10  $\mu$ M in acute (1 hour) and chronic (5 days) assays. Nedocromil prevents early- and late-phase bronchoconstriction in a guinea pig model of asthma induced by ovalbumin.<sup>2</sup> It also prevents conjunctival edema and erythema and reduces mast cell degranulation in a rat model of conjunctivitis when administered intravenously at a dose of 2 mg/kg.<sup>3</sup> Formulations containing nedocromil have been used in the treatment of allergic conjunctivitis and asthma.

# References

- 1. Rubinchik, E., Norris, A., and Levi-Schaffer, F. Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Int. J. Immunopharmacol. 17(7), 563-570 (1995).
- 2. Hutson, P.A., Holgate, S.T., and Church, M.K. Inhibition by nedocromil sodium of early and late phase bronchoconstriction and airway cellular infiltration provoked by ovalbumin inhalation in conscious sensitized guinea-pigs. Br. J. Pharmacol. 94(1), 6-8 (1988).
- 3. McGrath, L.E., Doherty, M.J., Easty, D.L., et al. Nedocromil sodium in two models of conjunctival immediate hypersensitivity. Adv. Ther. 17(1), 7-13 (2000).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

## SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/30/2022

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM